Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,751 sponsors by registered trial count).
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals: 9 sponsored US clinical trials, none currently recruiting.
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 1 trials.
Top-decile sponsor footprint
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
9 total, page 1 of 1
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
NCT03288454
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
NCT03172910
An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects
NCT02205905
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
NCT02206087
A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements
NCT02205827
PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin
NCT02206100
Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture
NCT02207205
Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban
NCT02207257
Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban
NCT01826266
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
How the Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals early-phase archive is shaped
9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Healthy (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.